Oncology Medical News about colon cancer cell growth;antibodies to prion protein

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Antibodies to prion protein inhibit human colon cancer cell growth
Tumor Biology, 06/16/09

McEwan JF et al. - In a trial to test whether antibodies to prion protein (PrP) could induce apoptosis and be utilised in the treatment of cancers, data suggest a potential pharmacological application for PrP antibodies in combination chemotherapy.

Methods

Various antibodies to PrP were screened in MTT proliferation assays with HCT 116 colon cancer cells.

Results

Antibodies were shown to have varying degrees of anti-proliferative activity, with 3F4 and 6D11 essentially inactive, vs other highly active antibodies.
BAR221 and F89/160.1.5 antibodies were particularly potent and afforded >40% reduction in proliferation at 50 μg/ml.
In combination therapy experiments, antibodies to PrP enhanced the effect of irinotecan, 5-FU, cisplatin, and doxorubicin to varying degrees.
Use of PrP antibody in vitro resulted in increased apoptosis as measured by reduced Bcl-2 expression.
In different colon cancer cell lines, antibody effectiveness correlated with tumour aggressiveness.
In an in vivo nude mouse bearing human HCT 116 xenografts, tumour growth was inhibited by treatment with PrP antibody.
47 days after treatment, at 9 mg/kg antibody in combination with irinotecan, tumour sizes were approximately 33% smaller vs animals receiving irinotecan alone.

<< Previous
Osteonecrosis of the jaw and use of bisphosphonates in adjuvant...

Next >>
Over-expression of CDH22 is associated with tumor progression in...